Orphan drug legislation
Will not be marked up by Senate Labor & Human Resources Committee prior to the August recess. Committee Chairman Kennedy (D-Mass.) has expressed concerns over modifications to the Orphan Drug Act that are contained in legislation sponsored by Rep. Waxman (D-Calif.) and Sen. Metzenbaum (D-Ohio). Kennedy is said to favor a straight reauthorization of the law without amendments. Waxman's bill is awaiting consideration on the House floor ("The Pink Sheet" July 23, T&G-3).
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.